Alternative splicing-related factor YT521: An independent prognostic factor in endometrial cancer

International Journal of Gynecological Cancer

Volumn 20, Issue 4, 2010, Pages 492-499

  Zhang, Bo ^a,b   Hausen, Axel Zur ^a   Orlowska Volk, Marzenna ^a   Jäger, Markus ^a   Bettendorf, Herta ^a   Stamm, Stefan ^c   Hirschfeld, Marc ^a   Yiqin, Ouyang ^a   Tong, Xiaowen ^b   Gitsch, Gerald ^a   Stickeler, Elmar ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b TONGJI UNIVERSITY   (China)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alternative splicing; Endometrial cancer; Prognostic factor; YT521

Indexed keywords

ISOPROTEIN; MESSENGER RNA; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; YT521 PROTEIN;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; EXON SKIPPING; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYSTERECTOMY; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NERVE TISSUE PROTEINS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA-BINDING PROTEINS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77952271631     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181d66ffe     Document Type: Article

References (23)

1. Clark TA, Schweitzer AC, Chen TX, et al. Discovery of tissue-specific exons using comprehensive human exon microarrays. Genome Biol. 2007;8: R64.
2. Kampa D, Cheng J, Kapranov P, et al. Novel RNAs identified from an in-depth analysis of the transcriptome of human chromosomes 21 and 22. Genome Res. 2004;14:331-342.
3. Cha JY, Lambert QT, Reuther GW, et al. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res. 2008;6:435-445.
4. Li L, Ryser S, Dizin E, et al. Oncogenic BARD1 isoforms expressed in gynecological cancers. Cancer Res. 2007;67:11876-11885.
5. Gardina PJ, Clark TA, Shimada B, et al. Alternative splicing by a whole genome exon array and differential gene expression in colon cancer detected. BMC Genomics. 2006;7:325-342.
6. Hirschfeld M, zur Hausen A, Bettendorf H, et al. Alternative splicing of Cyr61 is regulated by hypoxia and significantly changed in breast cancer. Cancer Res. 2009;69:2082-2090.
7. Allemand E, Hastings ML, Murray MV, et al. Alternative splicing regulation by interaction of phosphatase PP2Cgamma with nucleic acidYbinding protein YB-1. Nat Struct Mol Biol. 2007;14:630-638.
8. Muraki M, Ohkawara B, Hosoya T, et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem. 2004;279:24246-24254.
9. Imai Y, Matsuo N, Ogawa S, et al. Cloning of a gene, YT521, for a novel RNA splicing-related protein induced by hypoxia/reoxygenation. Brain Res Mol Brain Res. 1998;53:33-40.
10. Hartmann AM, Nayler O, Schwaiger FW, et al. The interaction and colocalization of Sam68 with the splicing-associated factor YT521-B in nuclear dots is regulated by the Src family kinase p59 (fyn). Mol Biol Cell. 1999;10:3909-3926.
11. Nayler O, Hartmann AM, Stamm S. The ER repeat protein YT521-B localizes to a novel subnuclear compartment. J Cell Biol. 2000;150:949-962.
12. Rafalska I, Zhang Z, Benderska N, et al. The intranuclear localization and function of YT521-B is regulated by tyrosine phosphorylation. Hum Mol Genet. 2004;13:1535-1549.
13. Stoilov P, Rafalska I, Stamm S. YTH: a new domain in nuclear proteins. Trends Biochem Sci. 2002;27:495-497.
14. Stickeler E, Vogl FD, Denkinger T, et al. Soluble CD44 splice variants and pelvic lymph node metastasis in ovarian cancer patients. Int J Mol Med. 2000;6:595-601.
15. Mayer S, zur Hausen A, Watermann DO, et al. Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients. J Cancer Res Clin Oncol. 2008;134:1229-1235.
16. Watermann DO, Tang Y, Zur Hausen A, et al. Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. Cancer Res. 2006;66:4774-4780.
17. Sieuwerts AM, Usher PA, Meijer-van Gelder ME, et al. Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clin Chem. 2007;53:1280-1288.
18. Temel SG, Minbay FZ, Kahveci Z, et al. Microwave-assisted antigen retrieval and incubation with cox-2 antibody of archival paraffin-embedded human oligodendroglioma and astrocytomas. J Neurosci Methods. 2006;156:154-160.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
20. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
21. Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. APMIS. 2009;117:693-707.
22. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009;16:08-13.
23. Stoilov P, Daoud R, Nayler O, et al. Human tra2-beta1 autoregulates its protein concentration by influencing alternative splicing of its pre-mRNA. Hum Mol Genet. 2004;13:509-524.